Travere Therapeutics Inc (NAS:TVTX)
$ 6.16 -0.18 (-2.84%) Market Cap: 468.95 Mil Enterprise Value: 431.93 Mil PE Ratio: 0 PB Ratio: 6.33 GF Score: 54/100

Q3 2020 Retrophin Inc Earnings Call Transcript

Nov 05, 2020 / 09:30PM GMT
Release Date Price: $20.88 (-1.69%)
Operator

Ladies and gentlemen, thank you for standing by, and welcome to the Retrophin Third Quarter Financial Results and Corporate Update Call. (Operator Instructions) I would now like to turn the conference over to your speaker today, Mr. Chris Cline. Please go ahead, sir.

Chris Cline
Travere Therapeutics, Inc. - SVP of IR & Corporate Communications

Thank you, Federica. Good afternoon, and welcome to Retrophin's Third Quarter 2020 Financial Results and Corporate Update Call. Thank you all for joining us. I hope you all and your families remain well. Today's call will be led by our Chief Executive Officer, Dr. Eric Dube. Eric will be joined for the prepared remarks by our Chief Medical Officer, Dr. Noah Rosenberg; Peter Heerma, our Chief Commercial Officer; and our Chief Financial Officer, Laura Clague. Dr. Bill Rote, Senior Vice President of Research and Development, will join us for the Q&A session.

Before we begin, I would like to remind everyone that statements made during this call regarding matters that are not historical facts are forward

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot